Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 26;21(1):63.
doi: 10.1186/s12882-020-01722-y.

Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study

Raphaël Gaisne  1   2 , Morgane Péré  3 , Victorio Menoyo  4 , Maryvonne Hourmant  5 , David Larmet-Burgeot  5   6
Affiliations

Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study

Raphaël Gaisne et al. BMC Nephrol. .

Abstract

Background: Calcific Uremic Arteriolopathy (CUA) is a rare disease, causing painful skin ulcers in patients with end stage renal disease. Recommendations for CUA management and treatment are lacking.

Methods: We conducted a retrospective cohort study on CUA cases identified in western France, in order to describe its management and outcome in average clinical practices. Selection was based on the Hayashi diagnosis criteria (2013) extended to patients with eGFR < 30 mL/min/1.73m2. Dialyzed CUA cases were compared with 2 controls, matched for age, gender, region of treatment and time period.

Results: Eighty-nine CUA cases were identified between 2006 and 2016, including 19 non dialyzed and 70 dialyzed patients. Females with obesity (55.1%) were predominant. Bone mineral disease abnormalities, inflammation and malnutrition (weight loss, serum albumin decrease) preceded CUA onset for 6 months. The multimodal treatment strategy included wound care (98.9%), antibiotherapy (77.5%), discontinuation of Vitamin K antagonists (VKA) (70.8%) and intravenous sodium thiosulfate (65.2%). 40.4% of the patients died within the year after lesion onset, mainly under palliative care. Surgical debridement, distal CUA, localization to the lower limbs and non calcium-based phosphate binders were associated with better survival. Risks factors of developing CUA among dialysis patients were obesity, VKA, weight loss, serum albumin decrease or high serum phosphate in the 6 months before lesion onset.

Conclusion: CUA involved mainly obese patients under VKA. Malnutrition and inflammation preceded the onset of skin lesions and could be warning signs among dialysis patients at risk.

Trial registration: ClinicalTrials.gov identifier NCT02854046, registered August 3, 2016.

Keywords: Calcific uremic arteriolopathy; Calciphylaxis; Case-control study; ESRD; Vitamin K antagonist.

PubMed Disclaimer

Conflict of interest statement

VM reports receiving grant support from Meditor and consulting fees from Astellas. The other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of selection of Calcific Uremic Arteriolopathy cases
Fig. 2
Fig. 2
Survival among Calcific Uremic Arteriolopathy cases and the hemodialysis controls
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nigwekar SU, Kroshinksy D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis Off J Natl Kidney Found. 2015;66(1):133–146. doi: 10.1053/j.ajkd.2015.01.034. - DOI - PMC - PubMed
    1. Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60(1):324–332. doi: 10.1046/j.1523-1755.2001.00803.x. - DOI - PubMed
    1. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61(6):2210–2217. doi: 10.1046/j.1523-1755.2002.00375.x. - DOI - PubMed
    1. Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific uremic Arteriolopathy risk factors. J Am Soc Nephrol. 2016;27(11):3421–3429. doi: 10.1681/ASN.2015091065. - DOI - PMC - PubMed
    1. Brandenburg VM, Evenepoel P, Floege J, et al. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? Nephrol Dial Transplant. 2016;31(8):1211–1219. doi: 10.1093/ndt/gfw025. - DOI - PubMed

Publication types

MeSH terms

Associated data